Breast Cancer Treatment With Everolimus And Exemestane For Er Plus Women: Results Of The First Interim Analysis Of The Noninterventional Trial Brawo

578 Background: BRAWO is a German non-interventional study of 3000 patients with advanced or metastatic, hormone-receptor-positive and HER2-negative breast cancer treated with Everolimus (EVE) and exemestane (EXE). Here we report the results of the first preplanned interim analysis (IA). Methods: BRAWO collects data on the routine clinical treatment with EVE 10mg/d and EXE 25mg/d at about 400 sites. Main objectives are to extend the knowledge on a) the impact of physical activity on efficiency and quality of life, b) prophylaxis and management of stomatitis in clinical routine, and c) the sequence of therapy, when EVE is used in usual daily care. This first IA focuses on objectives b) and c). Results: 866 patients (pts) at 253 active sites were analyzed, 53.2% of pts were ongoing at data cut-off. Baseline characteristics: Median age: 66 yrs; median BMI: 25.8. ECOC 0-1: 90%; visceral metastasis: 55.0%; bone only metastasis: 25.1%. 28.8% pts received EVE and EXE as first treatment (first line), 30.3% as sec...